ARCHIVES

ORI Finds Misconduct By Harvard Physician On Cancer Protocol; Two Other Cases

This article is from The Cancer Letter archive.

Vol. 21 No. 23 | June 9, 1995

Download PDF Visit The Full Archive

Related Articles

AstraZeneca To Pay $335M In Illegal Pricing Penalties.

June 27, 2003

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

September 26, 2014

NCI Publishes FOA For Trials Network Program

July 27, 2012

Stereotactic Radiosurgery Improves Survival Without Whole-Brain Radiotherapy

September 27, 2013

Cooperative Groups: Insurer To Cover Patient Care Costs In Clinical Trials

December 4, 1998

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

April 27, 2012